STATE-OF-THE-ART PAPER
Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease
Not Validated
Sanjay Kaul, MD*, ,1,*,
Andrew A. Zadeh, MD*, ,1 and
Prediman K. Shah, MD*,
* Division of Cardiology, Cedars-Sinai Medical Center, University of California, Los Angeles, California.
David Geffen School of Medicine, University of California, Los Angeles, California.
Manuscript received January 24, 2006;
revised manuscript received March 28, 2006,
accepted April 4, 2006.
* Reprint requests and correspondence: Dr. Sanjay Kaul, Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048. (Email: kaul{at}cshs.org).
Homocysteine has been implicated in promoting atherosclerotic and thrombotic vascular disease. During the last decade, the utility of homocysteine in predicting risk for atherothrombotic vascular disease has been evaluated in several observational studies in a large number of patients. These studies show that the overall risk for vascular disease is small, with prospective, longitudinal studies reporting a weaker association between homocysteine and atherothrombotic vascular disease compared to retrospective case-control and cross-sectional studies. Furthermore, randomized controlled trials of homocysteine-lowering therapy have failed to prove a causal relationship. On the basis of these results, there is currently insufficient evidence to recommend routine screening and treatment of elevated homocysteine concentrations with folic acid and other vitamins to prevent atherothrombotic vascular disease. This review outlines the metabolism and pathophysiology of homocysteine, highlights the results of homocysteine observational and interventional trials, and presents areas of uncertainty and potential future work.
|
Abbreviations and Acronyms
| | CAD = coronary artery disease | | CVD = cardiovascular disease | | HOPE-2 = Heart Outcomes Prevention Evaluation-2 trial | | IHD = ischemic heart disease | | MACE = major adverse cardiac event | | MI = myocardial infarction | | MTHFR = methylene tetrahydrofolate reductase | | NORVIT = Norwegian Vitamin Trial | | tHcy = total homocysteine | | VISP = Vitamin Intervention for Stroke Prevention study |
|
This article has been cited by other articles:

|
 |

|
 |
 
T. Jax and T. Lauer
The Art of Primary Prevention and Risk Assessment: Homocysteine Revisited
Stroke,
March 1, 2009;
40(3):
670 - 671.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Bruce and T. K. Young
Prevalence and Risk Factors for Neuropathy in a Canadian First Nation Community
Diabetes Care,
September 1, 2008;
31(9):
1837 - 1841.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Getz and C. A. Reardon
Nutrition and Cardiovascular Disease
Arterioscler Thromb Vasc Biol,
December 1, 2007;
27(12):
2499 - 2506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S Wierzbicki
Homocysteine and cardiovascular disease: a review of the evidence
Diabetes and Vascular Disease Research,
June 1, 2007;
4(2):
143 - 149.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kaul, A. A. Zadeh, and P. K. Shah
Reply
J. Am. Coll. Cardiol.,
March 27, 2007;
49(12):
1371 - 1371.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Akhtar
Is Homocysteine a Risk Factor for Atherothrombotic Cardiovascular Disease?
J. Am. Coll. Cardiol.,
March 27, 2007;
49(12):
1370 - 1371.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Wilson, R. B. McCaw, L. Leo, E. Arning, S. Lhotak, T. Bottiglieri, R. C. Austin, and S. R. Lentz
Prothrombotic Effects of Hyperhomocysteinemia and Hypercholesterolemia in ApoE-Deficient Mice
Arterioscler Thromb Vasc Biol,
January 1, 2007;
27(1):
233 - 240.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|